Phase II Study of Dose-Adjusted EPOCH-Rituximab in Adults With Untreated Burkitt Lymphoma and c-MYC+ Diffuse Large B-Cell Lymphoma
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
National Institute of Allergy and Infectious Diseases (NIAID)
National Institute of Allergy and Infectious Diseases (NIAID)
National Institute of Allergy and Infectious Diseases (NIAID)
National Institute of Allergy and Infectious Diseases (NIAID)
National Institute of Allergy and Infectious Diseases (NIAID)
National Institute of Allergy and Infectious Diseases (NIAID)
National Institute of Allergy and Infectious Diseases (NIAID)
AIDS Malignancy Consortium
Centre hospitalier de l'Université de Montréal (CHUM)
National Institutes of Health Clinical Center (CC)
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Ontario Clinical Oncology Group (OCOG)
National Institute of Allergy and Infectious Diseases (NIAID)
National Institute of Allergy and Infectious Diseases (NIAID)
Ainos, Inc. (f/k/a Amarillo Biosciences Inc.
Abbott
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
NIH AIDS Clinical Trials Information Service
NIH AIDS Clinical Trials Information Service
NIH AIDS Clinical Trials Information Service
NIH AIDS Clinical Trials Information Service
NIH AIDS Clinical Trials Information Service
NIH AIDS Clinical Trials Information Service
NIH AIDS Clinical Trials Information Service
NIH AIDS Clinical Trials Information Service
NIH AIDS Clinical Trials Information Service
NIH AIDS Clinical Trials Information Service
NIH AIDS Clinical Trials Information Service